Get the Stockscreener App
28.54
0.14%
-0.04
After Hours:
28.56
0.02
+0.07%
Oculis Holding Ag stock is traded at $28.54, with a volume of 324.31K.
It is down -0.14% in the last 24 hours and up +23.28% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$28.58
Open:
$28.58
24h Volume:
324.31K
Relative Volume:
1.68
Market Cap:
$1.65B
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-14.30
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+3.82%
1M Performance:
+23.28%
6M Performance:
+57.51%
1Y Performance:
+34.12%
1-Day Range:
$28.40
$28.80
1-Week Range:
$27.30
$29.09
52-Week Range:
$14.00
$29.36
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
28.54 | 1.65B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Insider Trends: Whats next for Oculis Holding AG stockEarnings Miss & Community Consensus Stock Picks - baoquankhu1.vn
Aug Selloffs: Can Oculis Holding AG maintain sales growth2025 Technical Patterns & Safe Capital Growth Stock Tips - baoquankhu1.vn
What’s the outlook for Oculis Holding AG’s sector2025 Volatility Report & Fast Gaining Stock Reports - mfd.ru
Head to Head Review: Rezolute (NASDAQ:RZLT) versus Oculis (NASDAQ:OCS) - Defense World
(OCS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Risk Check: Is Oculis Holding AG Equity Warrant benefiting from interest rate changesQuarterly Market Summary & High Yield Stock Recommendations - baoquankhu1.vn
Oculis Holding AG Reports Q3 2025 Financial Results - MSN
Oculis (NASDAQ:OCS) Hits New 12-Month HighTime to Buy? - MarketBeat
Is Oculis Holding AG Equity Warrant attractive for institutional investorsJuly 2025 Volume & Technical Pattern Based Signals - mfd.ru
Oculis Holding AG (OCS) Stock Analysis: A Biotech Gem With 63.59% Potential Upside - DirectorsTalk Interviews
Oculis (NASDAQ:OCS) Hits New 52-Week HighStill a Buy? - MarketBeat
Trend Recap: Is Oculis Holding AG Equity Warrant a top pick in the sector2025 Pullback Review & Long-Term Growth Stock Strategies - baoquankhu1.vn
Jobs Data: Can Oculis Holding AG beat the S P 500Gold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Aug Highlights: Will Oculis Holding AG benefit from rate cutsMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Fundamentals Check: Is MRNOW stock trending bullishChart Signals & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy - MSN
Oculis Holding AG (OCS) Stock Analysis: Unveiling A 68% Upside Potential For Investors - DirectorsTalk Interviews
Patterns Watch: Is Oculis Holding AG Equity Warrant exposed to political riskEarnings Recap Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Oculis Holding AG's (NASDAQ:OCS) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$130m Last Week - 富途牛牛
Market Fear: Is Oculis Holding AG Equity Warrant forming higher highs and higher lows2025 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Portfolio Update: Will IPGP outperform tech stocksTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Update Report: Can Oculis Holding AG continue delivering strong returnsDay Trade & Safe Capital Allocation Plans - baoquankhu1.vn
Oculis Holding (OCS) Is Up 9.3% After FDA Breakthrough Status For Privosegtor And DME Plans - Sahm
Is Oculis Holding AG Equity Warrant stock positioned for digital transformation2025 Earnings Impact & Free High Return Stock Watch Alerts - Bollywood Helpline
Oculis (NASDAQ:OCS) Reaches New 1-Year HighHere's Why - MarketBeat
Trading Systems Reacting to (OCS) Volatility - Stock Traders Daily
Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation - Sahm
OCS: Late-stage pipeline targets DME, dry eye, and neuroprotection, with major milestones in 2024–2027 - TradingView
US Market Wrap: How does Oculis Holding AG compare to its peersJuly 2025 News Drivers & Community Consensus Stock Picks - baoquankhu1.vn
Forecast Cut: How does Hubbell Incorporated correlate with NasdaqInflation Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50 - Defense World
Oculis Holding AG (NASDAQ:OCS) Sees Significant Growth in Short Interest - MarketBeat
Market Outlook: Is Oculis Holding AG Equity Warrant a top pick in the sectorWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis - Yahoo Finance
Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis - simplywall.st
Why Oculis Holding AG stock could benefit from AI revolutionWeekly Trade Recap & Technical Pattern Based Signals - Улправда
Is Oculis Holding AG stock recession proofEarnings Growth Report & Smart Money Movement Alerts - Улправда
Oculis (NASDAQ:OCS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis - Indian Pharma Post
Why Oculis Holding AG Equity Warrant stock could rally in 2025 - Улправда
Can Oculis Holding AG Equity Warrant stock beat analyst upgradesJuly 2025 Spike Watch & Reliable Breakout Forecasts - Улправда
Will Oculis Holding AG stock maintain momentum in 2025Trade Exit Report & Expert Curated Trade Ideas - Улправда
IPO Launch: Why Oculis Holding AG stock is recommended by analystsWeekly Profit Report & Free Reliable Trade Execution Plans - Улправда
Can Oculis Holding AG (CR5) stock surprise with quarterly resultsMarket Movement Recap & Long-Term Capital Growth Ideas - ulpravda.ru
Why Oculis Holding AG Equity Warrant stock attracts global investorsCandlestick Trading Patterns & Low Risk Trading Plans - bollywoodhelpline.com
Weekly Earnings: Can Oculis Holding AG Equity Warrant stock beat analyst upgradesQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Will Oculis Holding AG Equity Warrant stock deliver consistent dividendsJuly 2025 Update & Long-Term Safe Investment Ideas - Улправда
Why Oculis Holding AG stock is recommended by analysts2025 Price Momentum & Low Risk High Reward Ideas - Улправда
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):